J&J’s Zytiga Helps Eliminate Early-Stage Prostate Cancer

Johnson & Johnson’s Zytiga, approved last year to treat metastatic prostate cancer, helped eliminate tumors in high-risk patients whose malignancy hadn’t yet spread, a small study found.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.